SCHEMBL16616103

SCHEMBL16616103

CCOC(=O)c1cc(OC(C)C)c(-c2ccc(F)cc2)c(C2CC2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPK1 P28482 1/20 0.41
KDM4E B2RXH2 5/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
FDFT1 P37268 1/20 0.40
LMNA P02545 2/20 0.39
HPGD P15428 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
CASP3 P42574 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
GCGR P47871 1/20 0.37
MAPK14 Q16539 1/20 0.37
CHRNA7 P36544 1/20 0.37
NR3C2 P08235 1/20 0.37
SSTR5 P35346 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18022482 0.89 ALDH1A1 (0.43) MAPTALDH1A1MAPK1KDM4ENPC1
SCHEMBL16056320 0.88 SSTR5 (0.46) MAPTKDM4ELMNAHPGDSSTR5
SCHEMBL17535858 0.84 SSTR5 (0.40) MAPTALDH1A1KDM4ENPC1RAB9A
SCHEMBL16056786 0.84 SSTR5 (0.45) SSTR5KCNH2PTGDRPTGDR2
SCHEMBL18022487 0.83 MAPT (0.45) MAPTALDH1A1MAPK1KDM4ENPC1
SCHEMBL18832526 0.82 ALDH1A1 (0.40) MAPTALDH1A1KDM4ELMNAHPGD
SCHEMBL17535381 0.80 SSTR5 (0.42) SSTR5KCNH2
SCHEMBL16056446 0.79 SSTR5 (0.43) LMNASSTR5POLBKCNH2
SCHEMBL16616183 0.77 PTGER1 (0.43) MAPTALDH1A1MAPK1NPC1RAB9A
SCHEMBL16616338 0.77 MAPT (0.40) MAPTALDH1A1MAPK1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3055309-B1 ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) TAKEDA PHARMACEUTICALS CO (JP) 2018-06-13 EP disclosed
US-9751878-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-09-05 US disclosed
US-20160237087-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-08-18 US disclosed
EP-3055309-A1 ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) Takeda Pharmaceutical Company Limited (JP) 2016-08-17 EP disclosed
US-9353108-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-31 US disclosed
WO-2015052910-A1 ANTAGONISTS OF SOMATOSTATIN RECEPTOR SUBTYPE 5 (SSTR5) TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-16 WO disclosed
US-20150099777-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099777-A1 HETEROCYCLIC COMPOUND SSTR5, SSTR4, SSTR2 MAPT 3648/4885ALDH1A1 3197/4885MAPK1 403/4885
US-20160237087-A1 HETEROCYCLIC COMPOUNDS SSTR5, SSTR4, SSTR2 MAPT 3598/4885ALDH1A1 3012/4885MAPK1 369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.